An activation-defective mutant of the human cytomegalovirus IE2p86 protein inhibits NF-κB-mediated stimulation of the human interleukin-6 promoter
Author(s) -
Claire Gealy,
Christine Humphreys,
Vicky Dickinson,
Mark F. Stinski,
Richard Caswell
Publication year - 2007
Publication title -
journal of general virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.55
H-Index - 167
eISSN - 1465-2099
pISSN - 0022-1317
DOI - 10.1099/vir.0.82925-0
Subject(s) - biology , activator (genetics) , mutant , promoter , gene , nf κb , microbiology and biotechnology , human cytomegalovirus , nfkb1 , gene expression , transcription factor , signal transduction , genetics
The IE2p86 protein of human cytomegalovirus is an essential activator of early- and late-phase viral gene expression. Whilst IE2p86 activates expression of a number of cellular genes, it also represses certain cellular genes, particularly those activated by nuclear factor kappaB (NF-kappaB). As the interleukin-6 (IL-6) promoter can be activated by both NF-kappaB and IE2p86, it was examined whether there is competition between these two factors. Here, it is reported that both wild-type and mutant IE2p86 can block activation of the IL-6 promoter in response to interleukin-1beta. By using an artificial activator in which the activation domain of NF-kappaB is directed to the promoter by the GAL4 DNA-binding domain, it is shown that the mutant form of IE2p86 can inhibit NF-kappaB-mediated activation at a step subsequent to promoter recruitment. These data therefore suggest a novel mechanism for inhibition of NF-kappaB by IE2p86.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom